Lisata Therapeutics Inc. (LSTA)
Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's deepening collaboration with GATC Health. Mazzo explained that the partnership has evolved due to the complementary strengths of both organisations—Lisata's clinical and regulatory expertise and GATC's AI-powered drug discovery platform, MAT.
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer
Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, announced positive preliminary results from Cohort B of the ASCEND Phase 2b clinical trial evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). The ASCEND trial is a 158-patient, double-blind, randomized, placebo-controlled study assessing the addition of certepetide to standard-of-care gemcitabine and nab-paclitaxel.
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health
Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI). The expanded collaboration builds on prior work in which GATC provided AI-based analysis supporting Lisata's certepetide drug candidate.
Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants John Menditto - VP of IR and Corporate Communications David Mazzo - President and CEO James Nisco - SVP of Finance and Treasury and Chief Accounting Officer Kristen Buck - EVP of R&D and Chief Medical Officer Conference Call Participants Kemp Dolliver - Brookline Capital Market Pete Enderlin - MAZ Partners Operator Welcome to the Lisata Therapeutics First Quarter 2025 Financial Results and Business Update Conference Call. Currently, all participants are in listen-only mode.
Lisata eyes key trial milestones in 2025 as certepetide development gains momentum
Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its lead asset, certepetide, a novel peptide-based therapy being tested in a range of solid tumors. The New Jersey-based company said it remains focused on progressing certepetide through clinical and preclinical studies, with several important data readouts expected over the course of 2025 and into 2026, including results from the second cohort of its ASCEND trial in metastatic pancreatic cancer and preclinical work with Catalent's antibody-drug conjugate (ADC) platform.
Lisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company's strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC's technology will be used to analyze Lisata's lead candidate certepetide and identify potential new drug combinations.
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading drug discovery firm leveraging artificial intelligence. The partnership combines GATC's proprietary Multiomics Advanced Technology (MAT) AI platform with Lisata's expertise in drug development to reduce risks and improve efficiency in bringing new therapies to market.
Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants John Menditto - Vice President of Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer Kristen Buck - Executive Vice President of R&D and Chief Medical Officer James Nisco - Senior Vice President of Finance and Treasury and Chief Accounting Officer Conference Call Participants Sara Nik - H.C. Wainwright Peter Enderlin - MAZ Partners Steve Brozak - WBB Securities, LLC Kemp Dolliver - Brookline Capital Markets Operator Welcome to the Lisata Therapeutics' Full Year 2024 Financial Results and Business Update Conference Call.
Lisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progress
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a statement accompanying its full-year 2024 financial results. The pharmaceutical company highlighted progress in its clinical pipeline, including encouraging preliminary data from a Phase 2b pancreatic cancer trial.
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compay's pancreatic cancer trials. The company recently announced preliminary results from its Phase 2ASCEND trial at the ASCO Gastrointestinal conference.
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The iLSTA trial is being conducted at St John of God Subiaco Hospital in Western Australia, involving 30 patients divided into three treatment cohorts.
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is evaluating the efficacy of Lisata's novel therapy certepetide in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), an aggressive form of pancreatic cancer.
